Exploiting inhibitory Siglecs for desensitizing mast cells
Exploiting inhibitory Siglecs for desensitizing mast cells
批准号:
10219077
负责人:
JAMES C PAULSON
金额:
$61.27万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-24 至 2023-08-31
关键词:
AffinityAllergensAnaphylaxisAnti-Allergic AgentsAntibodiesAntigensAsthmaBasophilsBindingCaringCell DegranulationCellsCessation of lifeComplexDevelopmentDoseEpitopesExtrinsic asthmaFamilyGoalsHumanHypersensitivityIgEIgE ReceptorsIgG1IgG4Immune responseImmunizationImmunoglobulin GImmunologic TestsImmunotherapyIn VitroInterleukin 4 ReceptorLeadLigandsLiposomesMediatingModelingMonitorMusOralOvalbuminPassive Cutaneous AnaphylaxisPatientsPharmaceutical PreparationsPolysaccharidesProcessProductionRegimenRegulatory T-LymphocyteResearchSerumSymptomsSystemTestingTimeTransgenic MiceWorkallergic responseanti-IgEantigen challengebasedesensitizationfood allergenimmunological synapsemast cellmembermouse modelmutantnovelnovel strategiesomalizumabpassive sensitizationpreventreceptorrecruitresponsesialic acid binding Ig-like lectin
中文摘要
项目总结/摘要
肥大细胞和嗜碱性粒细胞引起的不必要的免疫应答有助于过敏症状,
哮喘在拟议的研究中,我们试图利用抑制性受体的Siglec家族的成员,
抑制肥大细胞(和嗜碱性粒细胞)抗原介导的IgE依赖性活化和脱粒,和
使它们对随后的抗原攻击脱敏。为此,我们将采用Siglec耐受性抗原
脂质体(STAL),其展示在肥大细胞上表达的Siglec的抗原和高亲和力聚糖配体
细胞当STAL遇到用抗原特异性IgE预致敏的肥大细胞时,
免疫球蛋白E受体(FcεRI)是一种聚糖配体,它将抑制性siglec募集到免疫突触。而
脂质体与抗原单独将有力地激活细胞,STAL上的聚糖配体招募细胞,
抑制性siglec阻断活化和脱粒。在人肥大细胞上表达的Siglecs之一是
CD33(Siglec-3)。我们已经发现,共展示抗原和高亲和力聚糖配体CD 33的STAL可以
在体外和在具有表达人CD 33肥大细胞的转基因小鼠中抑制肥大细胞脱颗粒,
在随后的抗原攻击时防止全身过敏反应。该项目的主要目标是
在致敏小鼠中优化CD 33靶向STAL以抑制IgE介导的全身过敏反应
模型目的是开发一种方法,提供持续的保护,防止抗原介导的过敏反应,
IgE/FcεRI轴介导的免疫应答。
0
英文摘要
PROJECT SUMMARY/ABSTRACT
Unwanted immune responses by mast cells and basophils contribute to the symptoms of allergies and
asthma. In the proposed research we seek to harness members of the Siglec family of inhibitory receptors to
suppress antigen mediated IgE dependent activation and degranulation of mast cells (and basophils), and
desensitize them to subsequent antigen challenge. To this end we will employ Siglec tolerizing antigenic
liposomes (STALs) that display both an antigen and high affinity glycan ligand of a Siglec expressed on mast
cells. When STALs encounter a mast cell pre-sensitized with antigen specific IgE bound to the high affinity
IgE receptor (FcεRI), the glycan ligand will recruit the inhibitory siglec to the immunological synapse. While
liposomes with antigen alone will powerfully activate the cells, the glycan ligand on STALs recruits the
inhibitory siglec blocking activation and degranulation. One of the Siglecs expressed on human mast cells is
CD33 (Siglec-3). We have found that STALs co-displaying antigen and high affinity glycan ligands CD33 can
suppress mast cell degranulation in vitro and in transgenic mice with mast cells expressing human CD33 can
protect against systemic anaphylaxis upon subsequent antigen challenge. Major aims of this project are to
optimize CD33 targeted STALs for suppressing IgE mediated systemic anaphylaxis, in sensitized mouse
models. The goal is to develop an approach to provide sustained protection against antigen mediated allergic
responses mediated by the IgE/FcεRI axis.
0
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Removing sialic acid ligands of CD28 to enhance T cell cancer immunotherapy
-
批准号:10668007
-
项目类别:
-
资助金额:$22.63万
-
财政年份:2023
-
负责人:JAMES C PAULSON
-
依托单位:
Siglec-targeted nanoparticles for treating mast cell mediated allergic disease
-
批准号:10331726
-
项目类别:
-
资助金额:$50.61万
-
财政年份:2018
-
负责人:JAMES C PAULSON
-
依托单位:
Exploiting inhibitory Siglecs for desensitizing mast cells
-
批准号:9789823
-
项目类别:
-
资助金额:$61.27万
-
财政年份:2018
-
负责人:JAMES C PAULSON
-
依托单位:
Exploiting inhibitory Siglecs for desensitizing mast cells
-
批准号:10468007
-
项目类别:
-
资助金额:$61.27万
-
财政年份:2018
-
负责人:JAMES C PAULSON
-
依托单位:
Siglec-targeted nanoparticles for treating mast cell mediated allergic disease
-
批准号:10097996
-
项目类别:
-
资助金额:$53.21万
-
财政年份:2018
-
负责人:JAMES C PAULSON
-
依托单位:
Influenza virus receptors on human airway epithelial cells
-
批准号:10226011
-
项目类别:
-
资助金额:$60.62万
-
财政年份:2015
-
负责人:JAMES C PAULSON
-
依托单位:
Influenza virus receptors on human airway epithelial cells
-
批准号:9887570
-
项目类别:
-
资助金额:$62.41万
-
财政年份:2015
-
负责人:JAMES C PAULSON
-
依托单位:
Influenza virus receptors on human airway epithelial cells
-
批准号:8963149
-
项目类别:
-
资助金额:$31.69万
-
财政年份:2015
-
负责人:JAMES C PAULSON
-
依托单位:
Influenza virus receptors on human airway epithelial cells
-
批准号:9233896
-
项目类别:
-
资助金额:$58.58万
-
财政年份:2015
-
负责人:JAMES C PAULSON
-
依托单位:
Influenza virus receptors on human airway epithelial cells
-
批准号:10676798
-
项目类别:
-
资助金额:$60.64万
-
财政年份:2015
-
负责人:JAMES C PAULSON
-
依托单位:
Influenza virus receptors on human airway epithelial cells
-
批准号:10456119
-
项目类别:
-
资助金额:$60.64万
-
财政年份:2015
-
负责人:JAMES C PAULSON
-
依托单位:
Glycan dependent epitopes of HIV broadly neutralizing antibodies
-
批准号:8777850
-
项目类别:
-
资助金额:$94.75万
-
财政年份:2014
-
负责人:JAMES C PAULSON
-
依托单位:
Glycan dependent epitopes of HIV broadly neutralizing antibodies
-
批准号:9291417
-
项目类别:
-
资助金额:$96.25万
-
财政年份:2014
-
负责人:JAMES C PAULSON
-
依托单位:
Glycan dependent epitopes of HIV broadly neutralizing antibodies
-
批准号:9079346
-
项目类别:
-
资助金额:$96.25万
-
财政年份:2014
-
负责人:JAMES C PAULSON
-
依托单位:
Glycan dependent epitopes of HIV broadly neutralizing antibodies
-
批准号:8892075
-
项目类别:
-
资助金额:$94.75万
-
财政年份:2014
-
负责人:JAMES C PAULSON
-
依托单位:
Inducing antigen specific B cell tolerance
-
批准号:8605833
-
项目类别:
-
资助金额:$47.38万
-
财政年份:2012
-
负责人:JAMES C PAULSON
-
依托单位:
Inducing antigen specific B cell tolerance
-
批准号:8271360
-
项目类别:
-
资助金额:$47.38万
-
财政年份:2012
-
负责人:JAMES C PAULSON
-
依托单位:
Inducing antigen specific B cell tolerance
-
批准号:8423690
-
项目类别:
-
资助金额:$44.53万
-
财政年份:2012
-
负责人:JAMES C PAULSON
-
依托单位:
IN SITU TRANS LIGANDS OF CD22 IDENTIFIED BY GLYCAN-PROTEIN PHOTOCROSS-LINKING
-
批准号:8365790
-
项目类别:
-
资助金额:$1.28万
-
财政年份:2011
-
负责人:JAMES C PAULSON
-
依托单位:
In vivo targeting of hematopoetic cells with glycan ligands of siglecs
-
批准号:8589372
-
项目类别:
-
资助金额:$36.54万
-
财政年份:2009
-
负责人:JAMES C PAULSON
-
依托单位:
海外基金